COVID-19 Vaccine (Pfizer-BioNTech)

Background

The Pfizer-BioNTech COVID-19 vaccine is an mRNA based vaccine which is approved in the United States to prevent symptomatic COVID-19 infection. The Pfizer-BioNTech was the first COVID-19 vaccine to be approved for distribution in the United States, and it was granted Emergency Use Authorization by the United States Food and Drug Administration (FDA) on 11 December 2020.

The approved dosing regimen is two doses, 30 μg each, administered 21 days apart. The vaccine is approved for individuals 16 years of age and older.

The vaccine is intended to prevent the COVID-19 illness, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Pfizer-BioNTech vaccine targets the SARS-CoV-2 spike glycoprotein (S).

Administration

• Type: SARS-CoV-2 spike glycoprotein (S) antigen encoded by RNA and formulated in lipid nanoparticles (LNPs).
• Dosage Forms: 2 doses of 30 μg each, administered 21 days apart.
• Routes of Administration: Intramuscular
• Common Trade Names: Pfizer-BioNTech COVID-19 Vaccine, Pfizer Vaccine

Special Populations

Renal Dosing

• Adult:
• Pediatric:

Hepatic Dosing

• Adult:
• Pediatric:

Contraindications

• Allergy to class/drug

Pharmacology

• Half-life:
• Metabolism:
• Excretion:

External Links

Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document- FDA

References

FDA Briefing Document, Pfizer-BioNTech COVID-19 Vaccine, https://www.fda.gov/media/144245/download, December, 2020. Accessed 21 December 2020